image
Healthcare - Biotechnology - NASDAQ - BM
$ 26.81
-3.02 %
$ 1.96 B
Market Cap
-112.25
P/E
CASH FLOW STATEMENT
25.7 M OPERATING CASH FLOW
93.14%
37.7 M INVESTING CASH FLOW
227.46%
12.3 M FINANCING CASH FLOW
720.47%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Kiniksa Pharmaceuticals, Ltd.
image
40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -43.2 M
Depreciation & Amortization 1.7 M
Capital Expenditures -277 K
Stock-Based Compensation 30.7 M
Change in Working Capital 24.8 M
Others 50.4 M
Free Cash Flow 25.4 M

Cash Flow

Millions
Dec-2024 Dec-2023 Dec-2022 Dec-2021 Dec-2020 Dec-2019 Dec-2018 Dec-2017 Dec-2016
OPERATING CASH FLOW
Net Income (43.2) 14.1 183.4 (157.9) (161.4) (161.9) (103.2) (64.9) (24.0)
Depreciation & Amortization 1.7 2.3 2.4 2.4 2.4 2.1 0.3 28 K 22 K
Deferred Income Tax 8.1 (33.8) (185.5) 11 K 4.4 (3.2) (1.0) (0.2) 46 K
Stock Based Compensation 30.7 27.1 25.1 25.2 20.9 15.1 5.7 0.9 0.4
Other Operating Activities 3.6 2.2 3.0 3.4 1.5 6.5 (1.1) 53 K 0.3
Change in Working Capital 24.8 1.4 (22.6) 0.7 (4.3) (17.0) 18.3 13.9 1.8
Cash From Operations 25.7 13.3 5.8 (126.3) (136.5) (158.4) (81.0) (50.2) (21.9)
INVESTING CASH FLOW
Capital Expenditures (0.3) (0.1) (0.1) (20.4) (0.3) (3.2) (5.3) 69 K 3 K
Other Items 37.9 (29.4) (8.0) 149.1 (23.2) 52.4 (233.9) 0 0
Cash From Investing Activities 37.7 (29.6) (8.1) 128.6 (23.4) 49.2 (239.2) 69 K 3 K
FINANCING CASH FLOW
Common Stock Repurchased (5.0) (2.2) (0.9) 5.9 0 0 0 0 0
Total Debt Repaid 0 0 0 0 0 0 0 0 0
Dividends Paid 0 0 0 0 0 0 0 0 0
Other Financing Activities 17.2 3.7 3.4 5.9 (1.1) 1.0 187.5 39.9 42.5
Cash From Financing Activities 12.3 1.5 2.5 5.9 227.1 84.1 346.7 39.9 42.5
CHANGE IN CASH
Net Change In Cash 75.6 (14.8) 0.2 8.2 67.1 (25.0) 26.5 (10.4) 20.6
FREE CASH FLOW
Free Cash Flow 25.4 13.2 5.7 (146.7) (136.8) (161.6) (86.3) (50.3) (21.9)